E Giuliani Meredith, Edith Filion, Sergio Faria, Vijayananda Kundapur, Toni Vu Thi Trinh Thuc, Benjamin H Lok, Srinivas Raman, Houda Bahig, Joanna M Laba, Pencilla Lang, Alexander V Louie, Andrew Hope, George B Rodrigues, Andrea Bezjak, Marie-Pierre Campeau, Marie Duclos, Scott Bratman, Anand Swaminath, Rohan Salunkhe, Andrew Warner, David A Palma
INTRODUCTION: The use of stereotactic body radiotherapy (SBRT) for tumors in close proximity to the central mediastinal structures has been associated with a high risk of toxicity. This study (BLINDED FOR REVIEW) aimed to determine the maximally tolerated dose (MTD) of SBRT for ultra-central (UC) non-small cell lung carcinoma (NSCLC), using a time-to-event continual reassessment methodology (TITE-CRM). METHODS: Patients with T1-3N0M0 (≤ 6 cm) NSCLC were eligible...
April 11, 2024: International Journal of Radiation Oncology, Biology, Physics